An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ENSEMBLE
- Sponsors Roche
- 10 Jan 2019 Planned number of patients changed from 978 to 1078.
- 10 Dec 2018 Planned End Date changed from 25 Feb 2023 to 22 Feb 2024.
- 10 Dec 2018 Planned primary completion date changed from 25 Feb 2023 to 22 Feb 2024.